New drug DA-5223 tested in tiny human trial
NCT ID NCT07633691
First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This early-phase trial is testing the safety and how the body handles an experimental drug called DA-5223 compared to a reference version. It involves 12 healthy adults who will receive single doses in a crossover design. The main goal is to measure drug levels in the blood and check for side effects. This study does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DA-5223 (an experimental drug)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bumin hospital
Gangseo-gu, Seoul, 07590, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibody tame the Body's allergic alarm system?
- Fingerprint sweat could replace oral swabs for drug testing
- Wearable tech puts hormone health to the test
- Can a better hazmat suit keep first responders safer and more effective?
- Home video tracking may expose the gap between clinic walking and real-world walking after stroke
- Avocado at breakfast: a secret weapon for blood sugar and fullness?